<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cancer cachexia-when proteasomal inhibition is not enough</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Jens</forename><surname>Fielitz</surname></persName>
							<email>jens.fielitz@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Molecular Cardiology, Experimental and Clinical Research Center (ECRC)</orgName>
								<orgName type="institution" key="instit1">Charité--Universitätsmedizin Berlin</orgName>
								<orgName type="institution" key="instit2">Max Delbrück Center (MDC) for Molecular Medicine in the Helmholtz Association</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Cardiology</orgName>
								<orgName type="department" key="dep2">Heart Center Brandenburg and Medical School Brandenburg (MHB)</orgName>
								<address>
									<settlement>Bernau</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Experimental and Clinical Research Center</orgName>
								<address>
									<addrLine>Lindenberger Weg 80</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cancer cachexia-when proteasomal inhibition is not enough</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">5AEC2F81C51044071C32C71B76A43957</idno>
					<idno type="DOI">10.1002/jcsm.12124</idno>
					<note type="submission">Received: 20 April 2016; Accepted: 29 April 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cancer</term>
					<term>cachexia</term>
					<term>wasting</term>
					<term>proteasome</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Cachexia is a life threatening syndrome associated with several diseases, such as end-stage heart failure, end-stage renal disease, chronic obstructive pulmonary disease, chronic inflammation (i.e.</s><s>rheumatoid arthritis), acquired immune deficiency syndrome, and cancer. 1,<ref type="bibr" target="#b1">2</ref></s><s>Cachexia is found in 31-87% of cancer patients especially in advanced disease stages. <ref type="bibr" target="#b2">3</ref></s><s>5]<ref type="bibr" target="#b5">[6]</ref> The incidence of cachexia in cancer patients is dependent on the type and site of the tumour.</s><s>While patients with non-Hodgkin's lymphoma, breast cancer, and sarcomas show low incidences, rates up to 83% in pancreatic cancer patients, and over 85% in patients with gastric cancer have been found.</s><s>8]<ref type="bibr" target="#b8">[9]</ref> Cancer cachexia affects the function of several organs such as muscle, adipose tissue, liver, brain, immune system, and heart, collectively decreasing patients' quality of life and worsening their prognosis.</s><s>Therefore, cachexia must be considered as a true multi-organ syndrome. <ref type="bibr" target="#b9">10</ref></s><s>ecause cancer cachexia leads to a decrease in physical performance and quality of life, 11 and is associated with poor survival (accounting for more than 20% of cancer deaths, <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> ) it is of major clinical relevance.</s><s>Even more so since cachectic patients show lower response rates to chemotherapy 7 and a reduced tolerance to anticancer treatment. <ref type="bibr" target="#b15">16</ref></s><s>Despite its importance, weight loss in cancer patients is rarely recognized, assessed, 17 or treated actively. <ref type="bibr" target="#b17">18,</ref><ref type="bibr" target="#b18">19</ref></s><s>Thus, cancer cachexia represents an important underappreciated clinical syndrome.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Muscle wasting is a major constituent of cancer cachexia</head><p><s>Cancer cachexia involves similar losses of muscle and adipose tissue and on a simplistic way, one could assume that this assures survival of the general organism.</s><s>However, this response differs from starvation induced cachexia where the majority of weight loss is from adipose rather than muscle tissue. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>In cancer cachexia, skeletal muscle wasting cannot be reversed by nutritional intervention arguing for cancerspecific signals that are involved in its pathogenesis.</s><s>The loss of muscle mass is accompanied by decreased strength, which is responsible for most of the cancer cachexia-associated symptoms, and increased mortality and morbidity of patients. <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23</ref></s><s>Wasting not only involves skeletal but also chest, diaphragm, and cardiac muscle leading to fatigue and respiratory complications. <ref type="bibr" target="#b2">3</ref> In fact, the majority of cancer deaths are related to respiratory <ref type="bibr" target="#b23">24</ref> or cardiac failure. <ref type="bibr" target="#b24">25</ref></s><s>Therefore, treatments capable to slow down, stop or even reverse muscle wasting in cancer cachexia may be beneficial for cancer patients in terms of physical independence, quality of life, tolerance to and sensitivity to anticancer treatments, and possibly reduce morbidity and mortality.</s><s>However, despite its clinical importance and the foreseen impact for patients, the pathophysiology of cachexia-associated muscle wasting is still poorly understood preventing the development of specific therapies.</s><s>Because maintenance of skeletal muscle mass and function is assured by a well-regulated balance of protein synthesis and degradation, a disturbed protein homeostasis with increased degradation and or decreased synthesis is a major contributor to muscle wasting in cancer. <ref type="bibr" target="#b25">26</ref></s><s>Increased protein degradation is caused by an elevated activity of muscular protein degrading systems predominantly the ubiquitinproteasome system (UPS), which plays an important role in cancer patients experiencing weight loss. <ref type="bibr" target="#b7">8</ref></s><s>otein degradation is important for skeletal muscle wasting in cancer</s></p><p><s>The UPS is the main protein degrading system in eukaryotic cells. <ref type="bibr" target="#b26">27</ref></s><s>9]<ref type="bibr" target="#b29">[30]</ref> Activation of the UPS in skeletal muscle leads to degradation of structural and contractile proteins, most notably myosin heavy chain, <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref> resulting in atrophy and decreased muscle function. <ref type="bibr" target="#b32">33</ref></s><s>Proteins targeted for proteasomal degradation are ubiquitinated by a hierarchical-ordered series of enzymes, including the ubiquitin-activating enzyme E1, ubiquitin-conjugating enzyme E2, and the ubiquitin E3 ligases, which allow the targeted proteins to be recognized by the 26S proteasome, a multi-subunit protease complex composed of the 20S catalytic core and 19S regulatory particles. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b33">34</ref></s><s>Substrate specificity of the UPS is assured by E3 ligases and substrate adaptor proteins. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b35">36</ref></s><s>In many models of cachexia, including cancer, UPS activation is thought to mediate muscle atrophy. <ref type="bibr" target="#b36">37</ref></s><s>During tumour cachexia, the UPS is up-regulated in skeletal muscle with an increased expression of the E3 ligase muscle-specific RING-finger 1 (MuRF1) and the substrate adaptor protein FBXO32/Atrogin-1. <ref type="bibr" target="#b37">38</ref></s><s>In a rat model of cachexia, induced by the Yoshida ascites hepatoma cells, UPS up-regulation was associated with increased Fbxo32/ Atrogin-1 gene expression <ref type="bibr" target="#b38">39</ref> and increased protein ubiquitination. <ref type="bibr" target="#b38">39</ref></s><s>This UPS activation in tumour-bearing mice is mediated by an increased activity of the transcription factor nuclear factor kB (NF-kB), which stimulates MuRF1 expression and muscle wasting. <ref type="bibr" target="#b39">40</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Communication between tumour and host</head><p><s>It remains uncertain how tumour cells communicate with the host to induce cancer cachexia.</s><s>The often anatomically distant locations between the tumour and the wasting musculature are suggestive for a signal released into the hosts' circulation by the tumour to cause muscle wasting in cachexia.</s><s>Especially, chronic inflammation with elevated levels of circulating inflammatory cytokines is consistently observed in cachectic cancer patients. <ref type="bibr" target="#b39">40</ref></s><s>Because chronic inflammation affects the function of several tissues (i.e.</s><s>skeletal muscle, fat, brain, and liver) it is an important cause of cancer cachexia. <ref type="bibr" target="#b40">41</ref></s><s>mong the best studied inflammatory cytokines promoting cachexia are tumour necrosis factor alpha (TNFα), interleukin-6 (IL-6), <ref type="bibr" target="#b41">42</ref> interleukin-1 (IL-1), and interferon gamma. <ref type="bibr" target="#b42">43</ref></s><s>hese cytokines are elevated in cancer <ref type="bibr" target="#b43">44</ref> and may together trigger muscle wasting, probably by increasing NF-kB or by causing the release of other cytokines. <ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46</ref></s><s>For example, TNFα, initially named cachectin, <ref type="bibr" target="#b46">47</ref> promotes anorexia <ref type="bibr" target="#b47">48</ref> and skeletal muscle wasting mainly through activation of the NF-kB pathway. <ref type="bibr" target="#b49">49</ref></s><s>Therefore, it has been tested if TNFα blockade is beneficial to prevent cancer cachexia.</s><s>Indeed, TNFα blockade improved cachexia-associated fatigue in a small group of cancer patients. <ref type="bibr" target="#b50">50</ref></s><s>However, in recent randomized controlled clinical trials anti-TNFα therapies using either the TNFα receptor-blocker etanercept in patients with incurable malignancies <ref type="bibr" target="#b51">51</ref> or the TNFα-specific monoclonal antibody infliximab in patients with metastatic non-small-cell lung cancer <ref type="bibr" target="#b52">52</ref> did not prevent or palliate weight loss or muscle atrophy.</s><s>Instead, infliximab increased fatigue and adversely affected patients' quality of life. <ref type="bibr" target="#b52">52</ref></s><s>These data suggest that targeting TNFα alone is not sufficient to prevent cachexia.</s><s>IL-6 and IL-1 are up-regulated in animal models of cancer cachexia, <ref type="bibr" target="#b53">53</ref> and IL-6 levels correlate with weight loss in certain human cancers. <ref type="bibr" target="#b54">54</ref></s><s>Interestingly, cancer cachexia can be attenuated in an adenocarcinoma mouse model treated with anti-IL-6 antibodies. <ref type="bibr" target="#b55">55</ref></s><s>However, if this strategy prevents muscle wasting in cancer patients needs to be shown.</s></p><p><s>As mentioned earlier, NF-kB is a key regulator of inflammatory responses and involved in muscle atrophy. <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b56">56,</ref><ref type="bibr" target="#b57">57</ref></s><s>In the majority of cells, NF-kB exists in an inactive form in the cytoplasm bound to the inhibitory protein IkB.</s><s>When stimulated with inflammatory cytokines (i.e.</s><s>TNFα, IL-1, and IL-6), NF-kB is activated by degradation of IkB proteins.</s><s>This occurs primarily via activation of IkB kinase, which phosphorylates IkB.</s><s>IkB phosphorylation leads to its ubiquitination and degradation by the proteasome. <ref type="bibr" target="#b58">58</ref></s><s>This allows free NF-kB to translocate to the nucleus and to stimulate the expression of its target genes. <ref type="bibr" target="#b59">59</ref></s><s>Because NF-kB activation is important for muscle atrophy, many approaches were undertaken to reduce its activity.</s><s>In mouse muscles, miss-expression of IkB to inhibit NF-kB reduced neurogenic atrophy in tumour-bearing mice. <ref type="bibr" target="#b39">40</ref></s><s>In mice lacking IkB kinase-β, neurogenic atrophy was also attenuated. <ref type="bibr" target="#b56">56</ref></s><s>Synthetic double-stranded oligodeoxynucleotides, which block NF-kB binding to promoter regions has been shown to inhibit cachexia in a mouse tumour model. <ref type="bibr" target="#b60">60</ref></s><s>Importantly, proteasome inhibitors interfere with the NF-kB pathway because they inhibit IkB degradation, which in turn prevents NF-kB activation. <ref type="bibr" target="#b61">61</ref></s><s>Because MuRF1 and FBXO32/Atrogin-1 are NF-kB target genes, proteasome inhibition is expected to prevent muscle atrophy by maintaining NF-kB in an inactive state, and thus preventing up-regulation of MuRF-1 and FBXO32/Atrogin-1.</s><s>Indeed, the proteasome inhibitor MG132 was shown to attenuate immobilization-induced atrophy.</s><s>Likewise, the proteasome inhibitor bortezomib has been shown to reduce neurogenic atrophy. <ref type="bibr" target="#b62">62</ref></s><s>oteasome inhibition as strategy to treat cancer cachexia Several groups investigated if UPS inhibition is beneficial to prevent muscle atrophy in different mouse models.</s><s>For this approach, mainly two-specific, potent and reversible proteasome inhibitors, MG132 and bortezomib, were used.</s><s>Both compounds inhibit degradation of ubiquitin-conjugated IkBα resulting in suppression of the NF-kB signalling pathway. <ref type="bibr" target="#b63">63</ref></s><s>n addition, bortezomib and MG132 reduce proteolysis in skeletal muscle in vitro <ref type="bibr" target="#b64">64,</ref><ref type="bibr" target="#b65">65</ref> and prevented muscle mass loss in an in vivo rat model of skeletal muscle wasting induced by denervation and cast immobilization of the hind limb. <ref type="bibr" target="#b62">62,</ref><ref type="bibr" target="#b66">66</ref></s><s>G132 was shown to preserve muscle and myofiber crosssectional area by down-regulating MuRF-1 and Fbxo32/ Atrogin-1 mRNA in a mouse model of hind limb-immobilization resulting in a diminished rehabilitation period. <ref type="bibr" target="#b67">67</ref></s><s>In addition, an increased proteasome activity was found in a mouse model for Laminin-deficient congenital muscular dystrophy type 1A (MDC1A).</s><s>Administration of MG132 increased lifespan, enhanced locomotive activity and enlarged muscle fibre diameter in MDC1A mice. <ref type="bibr" target="#b68">68</ref></s><s>Bortezomib had also beneficial effects in the MDC1A mouse model and in MDC1A patient cells. <ref type="bibr" target="#b69">69</ref></s><s>To this end, it was feasible to assume that proteasomal inhibition could be useful to block muscle wasting in cancer cachexia.</s><s>This hypothesis was subsequently tested by Penna et al. who report their findings in this issue of the Journal. <ref type="bibr" target="#b70">70</ref></s><s>Penna et al. investigated if bortezomib attenuates skeletal muscle wasting in two different and wellestablished animal models of tumour-induced muscle wasting. <ref type="bibr" target="#b70">70</ref></s><s>Cancer cachexia was induced by intraperitoneal injection of Yoshida AH-130 ascites hepatoma cells in rats and by subcutaneous inoculation of C26 carcinoma cells in mice.</s><s>As expected, bortezomib reduced proteasome activity on day 7 after transplantation of AH-130 tumour cells in the skeletal muscle, which was accompanied by a decreased NF-kB DNA-binding activity indicating that animals were effectively treated.</s><s>However, bortezomib administration did not prevent body weight loss and muscle wasting in the AH-130 host rats.</s><s>It also did not affect MuRF1 and Fbxo32/Atrogin-1 expression.</s><s>Likewise, bortezomib did not prevent body and muscle weight loss 12 days after tumour implantation in C26-bearing mice.</s><s>These data together with the published body of evidence indicate that the pathophysiology of cancer cachexia possibly involves additional NF-kB-and proteasome-independent protein degrading systems, such as autophagy and calpain proteases.</s><s>2]<ref type="bibr" target="#b73">[73]</ref> In a small cohort, lung cancer patients presented increased levels of the autophagy mediators BCL2/adenovirus E1B 19 kDa interacting protein 3 and light chain 3B, and the transcription factor FOXO1, which promotes autophagy. <ref type="bibr" target="#b71">71</ref></s><s>Similarly, in another study performed on esophageal cancer patients vs. weight-stable non-cancerous control patients, autophagy was identified as the main promoter of skeletal muscle proteolysis. <ref type="bibr" target="#b74">74</ref></s><s>Also calpain proteases have been proposed to initiate protein degradation during cachexia; <ref type="bibr" target="#b75">75,</ref><ref type="bibr" target="#b76">76</ref> however, limited information concerning their role in muscle wasting is available. <ref type="bibr" target="#b38">39</ref></s><s>Of note, in contrast to the data of Penna et al., the proteasome inhibitor MG132 was found to attenuate weight loss and muscle atrophy, and increased spontaneous activity and survival time in a C26-tumour-induced cancer cachexia mouse model. <ref type="bibr" target="#b77">77</ref></s><s>Together with other studies in which treatment with MG132 was shown to be effective in preventing muscle dystrophy, <ref type="bibr" target="#b78">78</ref> disuse-induced atrophy, <ref type="bibr" target="#b67">67</ref> and immobilization-mediated skeletal muscle atrophy, <ref type="bibr" target="#b79">79</ref> these data indicate that MG132 could be useful to prevent cancer cachexia.</s><s>However, MG132 also inhibits cathepsin and calpain proteases, <ref type="bibr" target="#b80">80</ref> which might partially explain its favourable treatment effects and the differences between MG132 and bortezomib used by Penna et al.. Therefore, the individual contribution of specific protein degrading systems and proteases in cancer cachexia as well as the effect of their inhibition as treatment option needs to be defined.</s><s>In addition, MG132 also reduced the tumour burden with a reduction in tumour volume and weight. <ref type="bibr" target="#b77">77</ref></s><s>Because tumours seem to interact with the host by factors that induce muscle wasting a reduction in tumour size will also lead to their decrease, which may result in less wasting.</s><s>Therefore, it is difficult to decide if proteasome inhibition by MG132 in muscle or in the tumour or both together reduced the occurrence of cancer cachexia in this mouse model.</s><s>A side-by-side comparison of bortezomib and MG132 in C26-bearing mice could show if this accounts for the differences of both studies.</s></p><p><s>In addition, despite the large body of evidence supporting the UPS as a major driver of muscle atrophy in animal models investigations of UPS components or activity in patient material are non-conclusive.</s><s>2]<ref type="bibr" target="#b83">[83]</ref><ref type="bibr" target="#b84">[84]</ref> Of note, there is no convincing evidence for increased UPS-mediated proteolysis in skeletal muscle biopsies of cachectic cancer patients. <ref type="bibr" target="#b71">71,</ref><ref type="bibr" target="#b85">85</ref></s><s>Investigations of UPS activity in biopsies of the quadriceps muscle have shown similar levels to healthy controls in patients with lung cancer and weight loss below 10%. <ref type="bibr" target="#b85">85</ref></s><s>Another study in lung cancer patients with low weight loss found no changes in UPS components. <ref type="bibr" target="#b86">86</ref></s><s>In contrast, in gastric cancer patients with average weight loss of 5%, increased UPS activity was measured compared with controls. <ref type="bibr" target="#b87">87</ref></s><s>These data implicate that there are certain forms of muscle atrophy and forms of cancer cachexia, respectively, where UPS-mediated proteolysis is not the main pathway in the disease process and proteasome inhibition will therefore not be able to attenuate the atrophy response.</s><s>This hypothesis is strengthened by data from non-cancer patients and animal models.</s><s>For example, the UPS is activated in muscle of patients with intensive care unit-acquired weakness <ref type="bibr" target="#b81">81</ref> and mice with polymicrobial sepsis. <ref type="bibr" target="#b88">88,</ref><ref type="bibr" target="#b89">89</ref></s><s>Accordingly, mice exposed to endotoxin, a cell wall component of gram-negative bacteria, display enhanced proteolytic activity in the diaphragm leading to a reduction in muscle mass, force, and protein content.</s><s>However, proteasome inhibition of endotoxin-treated mice did not prevent reductions in diaphragm-specific force generation indicating that inhibition of proteasome-mediated proteolysis alone does not prevent endotoxin-induced reductions in diaphragm force generation. <ref type="bibr" target="#b90">90</ref></s><s>These data indicate that proteasome inhibition is not effective in each and every model of muscle atrophy.</s></p><p><s>In general, bortezomib is well tolerated by patients.</s><s>Nevertheless, it is associated with some toxicity, such as nausea, diarrhoea, fatigue, and generalized weakness.</s><s>Indeed, proteasome inhibition is a double-edged sword as the proteasome mediates degradation of a multitude of proteins involved in critical biological processes and its inhibition possibly promotes protein accumulation that may cause proteotoxic effects.</s><s>Penna et al. described that bortezomib exerted a transient toxicity, which led to a reduced food intake in their animals. <ref type="bibr" target="#b70">70</ref></s><s>Because food deprivation increases MuRF1 and Fbxo32/Atrogin-1 expression and causes muscle atrophy, <ref type="bibr" target="#b89">89</ref> this side effect is important for data interpretation.</s><s>Even if bortezomib would have inhibited cachexia, the treatment-associated reduced food intake could have counteracted this effect.</s></p><p><s>Finally, caution is needed when interpreting animal models of cancer cachexia to the true cachexia phenotype in patients.</s><s>Penna et al. used well-established models of cancer cachexia.</s><s>However, these models do have their limitations; the young age and rapid progression of inoculated tumour cells are only few of them.</s><s>Furthermore, analysis 7 days after injection of AH-130 cells and 12 days after C26 transplantation, respectively, argues for an acute cachexia model.</s><s>These points do not reflect the clinical situation in tumour patients where cachexia develops over a longer period in mainly older patients.</s><s>Further studies also need to consider that cancer cachexia is a continuum with at least three stages of clinical relevance including pre-cachexia, cachexia and refractory cachexia. <ref type="bibr" target="#b91">91</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cancer cachexia is a multifactorial syndrome</head><p><s>In conclusion, we need to realize that not a single cytokine or signalling pathway is responsible for cancer cachexia; it is rather caused by a multitude of factors and signalling pathways that we only begin to understand.</s><s>Therefore, it is unlikely that treatments targeting only one aspect of the syndrome, such as the proteasome or individual cytokines, will effectively block its pathogenesis or progression.</s><s>Cachexia itself is a multifactorial syndrome that might phenotypically appear similar.</s><s>However, the appearance of a patient does not provide mechanistic information.</s><s>The path towards the cachectic phenotype is most likely different for various tumour types.</s><s>When the pathway responsible for the cachectic phenotype is uncertain, it is difficult to develop or apply the right treatment.</s><s>The data from Penna et al. should encourage us to look into proteasome-and NF-kB-independent signalling pathways involved in cancer cachexia and identify novel targets to treat this syndrome.</s><s>Further studies are needed to elucidate precise signalling pathways involved in cancer cachexia; and first steps towards this direction are already being taken. <ref type="bibr" target="#b92">92,</ref><ref type="bibr" target="#b93">93</ref></s><s>Some of the factors increased in cancer cachexia, such as angiotensin II, <ref type="bibr" target="#b94">94</ref> and the transforming growth factor beta family members myostatin <ref type="bibr" target="#b95">95</ref> and activin A, <ref type="bibr" target="#b96">96</ref> have already been identified.</s><s>Especially, myostatin and activin A are up-regulated in patients with various types of malignancies (for a review, see <ref type="bibr" target="#b97">97</ref> ).</s><s>Myostatin inhibits muscle growth and its overexpression promotes it. <ref type="bibr" target="#b98">98</ref></s><s>Therefore, inhibition of myostatin-activin A signalling is an attractive therapeutic target for treatment of cancer-associated muscle wasting.</s><s>Indeed, blockade of activin receptor IIB (ActRIIB), the receptor for activin A and myostatin and other transforming growth factor beta family members, was sufficient to prevent cachexia, increased muscle function and even prolonged survival in several cancer cachexia mouse models. <ref type="bibr" target="#b99">99,</ref><ref type="bibr" target="#b100">100</ref></s><s>This study showed that inhibition of cachexia has direct impact on cancer death. <ref type="bibr" target="#b99">99</ref></s><s>If myostatin inhibitors are beneficial as therapies for cancer, associated muscle wasting is currently being tested in clinical trials.</s><s>Further mechanisms, which are involved in the pathogenesis of cancer cachexia include growth differentiation factor-15, macrophage inhibitory cytokine-1, 101,102 leukaemia inhibitory factor, 103 Fn14, <ref type="bibr" target="#b105">104</ref> signal transducer and activator of transcription 3, 105 parathyroid hormone-related protein, <ref type="bibr" target="#b107">106</ref> and histone deacetylases; <ref type="bibr" target="#b108">107</ref> and this list is steadily increasing. <ref type="bibr" target="#b92">92,</ref><ref type="bibr" target="#b93">93</ref></s><s>Future studies need to be performed in a tumour-specific and disease stage-dependent manner to answer the question why certain cancers are more prone to cause cachexia than others, and to identify tumour-specific differences in cachexia pathways.</s><s>Information gained by those studies will be useful to develop target and disease stage-specific treatments.</s><s>Although animal models are useful in this regard they may or may not reflect the situation in patients at advanced tumour stages, and we need to appreciate this limitation cautiously.</s><s>Results from treatment studies on cachexia animal models that could not be successfully confirmed in patients should encourage us to intensify collaboration between clinicians and basic scientists to promote patient-based research and to tackle this life-threatening syndrome.</s></p></div>			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 239-245 DOI: 10.1002/jcsm.12124</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The author certifies that he complies with the ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. <ref type="bibr" target="#b109">108</ref></s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>None declared.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Muscle wasting in disease: molecular mechanisms and promising therapies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="58" to="74" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevalence, incidence and clinical impact of cachexia: facts and numbers-update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="261" to="263" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prevention and treatment of cancer cachexia: new insights into an old problem</title>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bossola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bellantone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Rossi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="31" to="41" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Cancer anorexia and cachexia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nutrition</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="438" to="442" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Uncomplicated starvation versus cancer cachexia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brennan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2359" to="2364" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Madeddu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gramignano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Serpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Massa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nutrition</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="305" to="313" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Dewys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Begg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Lavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Band</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Bertino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="491" to="497" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Mechanisms of cancer cachexia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="381" to="410" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ABC of palliative care. Anorexia, cachexia, and nutrition</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bruera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="1219" to="1222" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Cancer cachexia: understanding the molecular basis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stemmler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lopez-Soriano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="754" to="762" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Moses</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Slater</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Preston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fearon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="996" to="1002" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The lethal phenotype of cancer: the molecular basis of death due to malignancy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Loberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Tomlins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Chinnaiyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Pienta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="225" to="241" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Cancer cachexia: developing multimodal therapy for a multidimensional problem</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fearon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Cancer</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1124" to="1132" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Cancer anorexia-cachexia syndrome: current issues in research and management</title>
		<author>
			<persName><forename type="first">A</forename><surname>Inui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="72" to="91" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Cancer cachexia study G. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Voss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hustead</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="1345" to="1350" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Cachexia worsens prognosis in patients with resectable pancreatic cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Heiligensetzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Krakowski-Roosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Buchler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Friess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Martignoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gastrointest Surg: Official J Society Surg Alimentary Tract</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1193" to="1201" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">A questionnaire study of the approach to the anorexia-cachexia syndrome in patients with cancer by staff in a district general hospital. Support Care Canc</title>
		<author>
			<persName><forename type="first">D</forename><surname>Churm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Andrew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Holden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hildreth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hawkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Official J Multinational Assoc Supportive Care Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="503" to="507" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The views and practice of oncologists towards nutritional support in patients receiving chemotherapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Spiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baldwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Andreyev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="431" to="434" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Is malnutrition still a risk factor of postoperative complications in gastric cancer surgery?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Pacelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bossola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Tortorelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Papa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Doglietto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="398" to="407" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cancer cachexia: metabolic alterations and clinical manifestations</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nutrition</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Distinguishing starvation from cachexia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Geriatr Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="883" to="891" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Mcmillan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Nutr Soc</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="257" to="262" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Understanding the mechanisms and treatment options in cancer cachexia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arends</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baracos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="90" to="99" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">An investigation of the cause of death from cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Houten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Reilley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="111" to="116" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Why cachexia kills: examining the causality of poor outcomes in wasting conditions</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stenvinkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kovesdy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="89" to="94" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">On our way to targeted therapy for cachexia in cancer?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Boddaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Gerritsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Pinedo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="335" to="340" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Proteasome inhibitors in cancer therapy: lessons from the first decade</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Z</forename><surname>Orlowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kuhn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Canc Res: Official J Am Assoc Canc Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1649" to="1657" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The ubiquitin-proteasome proteolytic pathway</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ciechanover</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="13" to="21" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Ubiquitin, proteasomes, and the regulation of intracellular protein degradation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hochstrasser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Cell Biol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="215" to="223" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Protein degradation and protection against misfolded or damaged proteins</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">426</biblScope>
			<biblScope unit="page" from="895" to="899" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3</title>
		<author>
			<persName><forename type="first">J</forename><surname>Fielitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Shelton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Latif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Spencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Glass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="2486" to="2495" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Muscle RINGfinger 2 and 3 maintain striated-muscle structure and function</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lodka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pahuja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geers-Knörr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scheibe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hamati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Sarcopenia Muscle</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Signalling pathways that mediate skeletal muscle hypertrophy and atrophy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Glass</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Cell Biol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="87" to="90" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">New insights into the mechanisms and importance of the proteasome in intracellular protein degradation</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Akopian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Kisselev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rohrwild</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Chem</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="131" to="140" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The ubiquitin-proteasome system in cardiac physiology and pathology</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Powell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Heart Circ Physiol</title>
		<imprint>
			<biblScope unit="volume">291</biblScope>
			<biblScope unit="page" from="H1" to="H19" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ciechanover</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="S7" to="19" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Identification of ubiquitin ligases required for skeletal muscle atrophy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Bodine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Latres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baumhueter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nunez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="1704" to="1708" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Muscle wasting in cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fearon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2215" to="2229" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Devivo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Hoyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">268</biblScope>
			<biblScope unit="page" from="E996" to="1006" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">IKKbeta/NF-kappaB activation causes severe muscle wasting in mice</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Frantz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Tawa</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Melendez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Lidov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="285" to="298" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Counteracting inflammation: a promising therapy in cachexia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Lopez-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Rev Oncog</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="253" to="262" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Interleukin-6 and cachexia in ApcMin/+ mice</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Baltgalvis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Pena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Muga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Carson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Regul Integr Comp Physiol</title>
		<imprint>
			<biblScope unit="volume">294</biblScope>
			<biblScope unit="page" from="R393" to="401" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maccio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Massa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Mudu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mulas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Med (Berl)</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="554" to="561" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor-alpha and muscle wasting: a cellular perspective</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Reid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">P</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Respir Res</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="269" to="272" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Rel A/p65 is required for cytokine-induced myotube atrophy</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yamaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Jackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kandarian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Cell Physiol</title>
		<imprint>
			<biblScope unit="volume">303</biblScope>
			<biblScope unit="page" from="C135" to="142" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Tweardy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Garibotto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Metab</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="368" to="379" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Torti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dieckmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Beutler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Ringold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="page" from="867" to="869" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Jakubowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Casper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Gabrilove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Templeton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Sherwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Oettgen</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol: Official J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="298" to="303" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor-alphainducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weinman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Boldogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Brasier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">274</biblScope>
			<biblScope unit="page" from="787" to="794" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Monk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Waite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Schaaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Otterson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol: Official J Am Soc Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1852" to="1859" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">A placebo-controlled double blind trial of etanercept for the cancer anorexia/ weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Dakhil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sloan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Kugler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Rowland</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="1396" to="1403" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">A placebocontrolled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Ritter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dueck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Nikcevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Luyun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="234" to="239" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Catalano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fortunati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Arena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aragno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Danni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="429" to="436" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">The relationship between weight loss and interleukin 6 in nonsmall-cell lung cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Mcmillan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Crilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Mcardle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Milroy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1560" to="1562" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Evidence for the involvement of interleukin 6 in experimental cancer cachexia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Strassmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jacob</forename><surname>Co</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="1681" to="1684" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration</title>
		<author>
			<persName><forename type="first">F</forename><surname>Mourkioti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kratsios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Luedde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Adami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="2945" to="2954" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Hunter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kandarian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="1504" to="1511" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The IKK NF-kappa B system: a treasure trove for drug development</title>
		<author>
			<persName><forename type="first">M</forename><surname>Karin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">M</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="17" to="26" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>May</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Kopp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="225" to="260" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kawamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Morishita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tomita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lacey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aketa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tsujimoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gene Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="91" to="97" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Traenckner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wilk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Baeuerle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="5433" to="5441" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Beehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Sleph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Benmassaoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Grover</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Biol Med</title>
		<imprint>
			<biblScope unit="volume">231</biblScope>
			<biblScope unit="page" from="335" to="341" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Inoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Matsuura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mikami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Uza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="172" to="182" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Tawa</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Odessey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="197" to="203" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo</title>
		<author>
			<persName><forename type="first">D</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Gang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pritts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Hasselgren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="215" to="221" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Hindlimb casting decreases muscle mass in part by proteasome-dependent proteolysis but independent of protein synthesis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Krawiec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Frost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Vary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Jefferson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">289</biblScope>
			<biblScope unit="page" from="E969" to="E980" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">The proteasome inhibitor MG132 reduces immobilizationinduced skeletal muscle atrophy in mice</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Caron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haroun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leblanc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Trensz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guindi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Amrani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Musculoskelet Disord</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">185</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Proteasome inhibition improves the muscle of laminin alpha2 chain-deficient mice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Carmignac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Quere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Durbeej</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="541" to="552" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Bortezomib partially improves laminin alpha2 chain-deficient muscular dystrophy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Korner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Fontes-Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Holmberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Carmignac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Durbeej</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="1518" to="1528" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</title>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bonetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Minero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rossi</forename><surname>Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<idno type="DOI">10.1007/jcsm.12057</idno>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Op Den Kamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Langen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Snepvangers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>De Theije</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Schellekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Laugs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="738" to="748" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Gosker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Schols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kapchinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bourbeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sandri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="1313" to="1320" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Coming back: autophagy in cachexia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Clin Nutr Metab Care</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="241" to="246" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients</title>
		<author>
			<persName><forename type="first">N</forename><surname>Tardif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klaude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thorell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rooyackers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1485" to="1492" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Ca(2+)-dependent proteolysis in muscle wasting</title>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reffo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Penna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Autelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Baccino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2134" to="2146" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Hasselgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pacelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Doglietto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="410" to="414" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cancer Res Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="1105" to="1115" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lipscomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Angela</forename><surname>Parkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Juusola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Winder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename></persName>
		</author>
		<idno type="DOI">10.1371/currents.RRN1286</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS Currents Muscular Dystrophy</title>
		<imprint>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Prevention of muscle disuse atrophy by MG132 proteasome inhibitor</title>
		<author>
			<persName><forename type="first">C</forename><surname>Jamart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Raymackers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Li</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Deldicque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Francaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="708" to="716" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Proteasome inhibitors: from research tools to drug candidates</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Kisselev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chem Biol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="739" to="758" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness</title>
		<author>
			<persName><forename type="first">T</forename><surname>Wollersheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Woehlecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krebs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hamati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lodka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Luther-Schroeder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intensive Care Med</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="528" to="538" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Protein metabolism and gene expression in skeletal muscle of critically ill patients with sepsis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Klaude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tjader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wernerman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rooyackers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Sci</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="133" to="142" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle</title>
		<author>
			<persName><forename type="first">E</forename><surname>Edstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hagglund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ulfhake</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gerontol A Biol Sci Med Sci</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="663" to="674" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Doucet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Leger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Debigare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Joanisse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Caron</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="261" to="269" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Op Den Kamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Langen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Minnaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Kelders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Snepvangers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Hesselink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="112" to="117" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Jagoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gibson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Goodship</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Sci</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="353" to="361" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Increased muscle proteasome activity correlates with disease severity in gastric cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bossola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Costelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grieco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pacelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">237</biblScope>
			<biblScope unit="page" from="384" to="389" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Inflammation-Induced Acute Phase Response in Skeletal Muscle and Critical Illness Myopathy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Langhans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weber-Carstens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hamati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0092048</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wollersheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Persicke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Langhans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">545</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Effect of proteasome inhibitors on endotoxin-induced diaphragm dysfunction</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Supinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vanags</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Callahan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Lung Cell Mol Physiol</title>
		<imprint>
			<biblScope unit="volume">296</biblScope>
			<biblScope unit="page" from="L994" to="L1001" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Definition and classification of cancer cachexia: an international consensus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Strasser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bosaeus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bruera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Fainsinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="489" to="495" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Ataxin-10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Schafer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">U</forename><surname>Oeing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rohm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Baysal-Temel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Lehmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Metabol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="67" to="78" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Proteomic analysis of media from lung cancer cells reveals role of 14-3-3 proteins in cachexia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Mclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Moylan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Horrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Andrade</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Frontiers Physiol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">136</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Mechanisms of cachexia in chronic disease states</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="250" to="256" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Myostatin is a novel tumoral factor that induces cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lokireddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Wijesoma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Sze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mcfarlane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">446</biblScope>
			<biblScope unit="page" from="23" to="36" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Role of activin A and myostatin in human cancer cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Loumaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Barsy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nachit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Frateur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Maanen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2030" to="2038" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Myostatin/activin pathway antagonism: molecular basis and therapeutic potential</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Q</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2333" to="2347" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Mcpherron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lawler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="83" to="90" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="531" to="543" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orpi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Massa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Capdevila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="37" to="43" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<monogr>
		<title level="m" type="main">Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC</title>
		<author>
			<persName><forename type="first">H</forename><surname>Johnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuffner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Bauskin</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1333" to="1340" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Anorexia/ cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1/ GDF15</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Husaini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Manandhar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Lee-Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Harriott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="239" to="243" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">A key role for leukemia inhibitory factor in C26 cancer cachexia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Seto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kandarian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Jackman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="19976" to="19986" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jenkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Laine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Emmrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Faou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="1365" to="1378" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Tweardy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page" from="11177" to="11187" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kleiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kazak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Baracos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">513</biblScope>
			<biblScope unit="page" from="100" to="104" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kulp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">L</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Frankhouser</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djv274</idno>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="315" to="316" />
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
